InvestmentPitch Media Video Discusses FSD Pharma’s Addition of Kevin Harrington, Author, “Shark Tank” Original, and Infomercial Pioneer to its Advisory Board

Rhea-AI Summary

FSD Pharma Inc. (NASDAQ:HUGE) has appointed Kevin Harrington, a prominent entrepreneur and former 'Shark Tank' investor, to its Advisory Board. Harrington, known for creating the modern infomercial, has launched over 20 businesses each exceeding $100 million in sales. His experience includes opening distribution in over 100 countries, providing FSD Pharma with valuable branding and marketing insights. Harrington aims to leverage his extensive network to expand the company's reach and enhance its product development, particularly in therapeutics addressing alcohol misuse. FSD Pharma's stock is currently trading at $1.80.

Positive

• The addition of Kevin Harrington is expected to enhance FSD Pharma's marketing and branding efforts.
• Harrington's extensive network may provide new business opportunities and partnerships.
• His experience in launching successful products could positively influence FSD Pharma's drug development strategies.

Negative

• Concerns may arise regarding the continuity and experience of FSD Pharma's existing team with new advisory influences.

VANCOUVER, British Columbia, March 01, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announced the addition of iconic entrepreneur Kevin Harrington to its Advisory Board. Kevin Harrington, inventor of the modern infomercial format, pioneer of the “As Seen on TV” brand, and one of the original “sharks” on the hit ABC show “Shark Tank”, has launched more than 20 businesses that have each grown sales in excess of $100 million as part of a career that has introduced 1,000+ products generating over $6 billion in global sales.

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company. The video is available for viewing on “InvestmentPitch” and on “YouTube”. If these links are not enabled, please visit www.InvestmentPitch.com and enter “FSD Pharma” in the search box.

His business experience spans the globe, including opening distribution outlets in more than 100 countries. A best-selling author, influencer, and venerable marketing expert frequently featured and quoted in leading media outlets, Mr. Harrington co-founded the Entrepreneurs’ Organization, a peer-to-peer network of more than 17,000 diverse business leaders with 220 chapters in 60+ countries. Mr. Harrington will be opening his vast rolodex to expand the reach of the company and its brands. With Mr. Harrington’s connections and assistance, FSD Pharma plans to expand its high-powered Advisory Board with the addition of other high profile business minds.

Zeeshan Saeed, FSD Pharma’s President and Co-Executive Chairman, stated: “Kevin has always been a visionary at the forefront of the dynamic marketing space, proving over decades the tremendous value he brings to companies he becomes involved with by sharing his branding expertise, network, and business insight. We welcome him to our Advisory Board and look forward to working with him strategically on our R&D programs and product development.”

Kevin Harrington, added: “Throughout my career, my investments have the common thread of ground-floor opportunities in research and development of products that I believe can be transformational, whether it be a beverage, kitchen utensil, or, in the case of FSD Pharma, a strong pipeline of therapeutics, which include potential products that may provide significant help in alcohol misuse cases. We have all seen the detrimental effects associated with irresponsible use of alcohol. It is an area ripe for innovation and I welcome the opportunity to participate in FSD Pharma’s goal to make important societal impact, particularly in that area.”

FSD Pharma Inc., through two wholly owned subsidiaries, has three drug candidates in different stages of development. FSD BioSciences is focused on pharmaceutical research and development of its lead compound, FSD201, a proprietary ultra-micronized PEA formulation, for the treatment of inflammatory diseases. In addition to Lucid-MS, Lucid Psycheceuticals is also focused on the development of Lucid-Psych a molecular compound identified for the potential treatment of mental health disorders, and expanding this category, the company is investigating other products addressing acute medical needs due to the abuse of drugs such as alcohol.

The shares are trading at US $1.80 on NASDAQ. For more information on the company’s drug candidates, please visit the company’s website, www.FSDpharma.com, or contact Zeeshan Saeed, Founder, President and Executive Co-Chairman, at 416-854-8884 or email zsaeed@FSDPharma.com or IR@FSDPharma.com.

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company’s story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

Disclaimer

The information in this Investmentpitch Media Ltd video is for the viewers information only. FSD Pharma has paid a fee not exceeding $2,000 in cash to have its current news release produced in video format. The corporate information is based on information that is publicly available. Any information provided by Investmentpitch Media Ltd., through its media services is not to be construed as a recommendation or suggestion or offer to buy or sell securities but is provided solely as an informational media service. Investmentpitch Media Ltd makes no warranties or undertakings as to the accuracy or completeness of this information. All due diligence should be done by the viewer or their financial advisor. Investing in securities is speculative and carries risk.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com

FAQ

What is the significance of Kevin Harrington joining FSD Pharma's Advisory Board?

Kevin Harrington's appointment to FSD Pharma's Advisory Board is significant due to his extensive entrepreneurial experience and successful track record in product launches, which could enhance the company's branding and strategic positioning.

How might Kevin Harrington's role impact FSD Pharma's stock?

Harrington's involvement could potentially boost investor confidence and interest in FSD Pharma, possibly leading to positive movements in the stock price.

What are FSD Pharma's drug development focuses?

FSD Pharma is focusing on developing therapeutics for neurodegenerative and inflammatory disorders, including products aimed at addressing alcohol misuse.

What is the current stock price of FSD Pharma?

As of the announcement, FSD Pharma's shares are trading at $1.80 on NASDAQ.